Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Immunotherapy
  • Melanoma
  • Receptors, Antigen, T-Cell, gamma-delta
  • T-Lymphocyte Subsets

abstract

  • High REC and RLC, low LDH, and absence of metastasis other than soft-tissue/lung are independent baseline characteristics associated with favorable OS of patients with melanoma treated with pembrolizumab. Presence of four favorable factors in combination identifies a subgroup with excellent prognosis. In contrast, patients with no favorable factors present have a poor prognosis, despite pembrolizumab, and additional treatment advances are still needed. A potential predictive impact needs to be further investigated. Clin Cancer Res; 1-10. ©2016 AACR.

publication date

  • November 15, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5572569

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-16-0127

PubMed ID

  • 27185375

Additional Document Info

volume

  • 22

number

  • 22